{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:14:10Z","timestamp":1774260850071,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":107,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue healing by stabilizing matrix proteins and protecting heparin-binding growth factors. In humans, an open self-controlled study suggested that the topical application of CACIPLIQ20 optimizes skin healing following surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To expand previous findings using a different CACIPLIQ20 administration regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-four females were referred for breast-reduction surgery. Each patient had their own control with 1 CACIPLIQ20-treated and 1 saline-treated control breast. The treated side (right or left) was randomly assigned by the operating surgeon. Scar appearance was assessed by 6 independent raters using a global visual scar comparison scale based on scar photographs. All raters were blinded toward the CACIPLIQ20-treated side.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The follow-up period following surgery ranged from 1 to 12 months with a median follow-up of 6 months. Overall, there was a mean improvement of 15.2% (SD = 26.7) in favor of CACIPLIQ20 (P = .016). On the CACIPLIQ20-treated side, the mean score per patient was above 20% in 11 patients and above 30% improvement in 8 cases. In contrast, only 3 patients were considered improved by at least 20% on the control side and only 1 above 30%. A comparison of different application regimens suggested that the best trend was obtained with a single administration of CACIPLIQ20 at Day 0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In conclusion, CACIPLIQ20 could represent an interesting scar prophylactic therapy, based on a single administration at the time of surgery, and without any known adverse effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 3<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asjof\/ojad031","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:46:04Z","timestamp":1679597164000},"source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars"],"prefix":"10.1093","volume":"5","author":[{"given":"Gilbert","family":"Zakine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Perruisseau-Carrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"T\u00e9ot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Barritault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2023070812255111500_ojad031-B1","doi-asserted-by":"publisher","first-page":"625376","DOI":"10.1155\/2009\/625376","article-title":"Cutaneous scarring: a clinical review","volume":"2009","author":"Baker","year":"2009","journal-title":"Dermatol Res Pract"},{"issue":"2","key":"2023070812255111500_ojad031-B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/wound.2016.0696","article-title":"Cutaneous scarring: basic science, current treatments, and future directions","volume":"2","author":"Marshall","year":"2018","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2023070812255111500_ojad031-B3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-030-44766-3_9","volume-title":"Textbook on Scar Management","author":"Mustoe","year":"2020"},{"issue":"8","key":"2023070812255111500_ojad031-B4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/dsu.0000000000000049","article-title":"Updated international clinical recommendations on scar management: part 1\u2014evaluating the evidence","volume":"40","author":"Gold","year":"2014","journal-title":"Dermatol Surg"},{"issue":"8","key":"2023070812255111500_ojad031-B5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/dsu.0000000000000050","article-title":"International Advisory Panel on Scar Management. Updated international clinical recommendations on scar management: part 2\u2014algorithms for scar prevention and treatment","volume":"40","author":"Gold","year":"2014","journal-title":"Dermatol Surg"},{"key":"2023070812255111500_ojad031-B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-030-44766-3_3","volume-title":"Textbook on Scar Management","author":"Darby","year":"2020"},{"issue":"3","key":"2023070812255111500_ojad031-B7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10719-016-9744-5","article-title":"RGTA(R) or ReGeneraTing agents mimic heparan sulfate in regenerative medicine: from concept to curing patients","volume":"34","author":"Barritault","year":"2017","journal-title":"Glycoconj J"},{"issue":"4","key":"2023070812255111500_ojad031-B8","first-page":"274","article-title":"New concepts in tissue repair: skin as an example","volume":"22","author":"Meddahi","year":"1996","journal-title":"Diabetes Metab"},{"issue":"2","key":"2023070812255111500_ojad031-B9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1524-475X.2008.00368.x","article-title":"RGTA OTR 4120, a heparan sulfate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full-thickness excisional wounds","volume":"16","author":"Tong","year":"2008","journal-title":"Wound Repair Regen"},{"issue":"6","key":"2023070812255111500_ojad031-B10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1524-475X.2009.00548.x","article-title":"Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120","volume":"17","author":"Tong","year":"2009","journal-title":"Wound Repair Regen"},{"issue":"4","key":"2023070812255111500_ojad031-B11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1524-475X.2011.00704.x","article-title":"Heparan sulfate glycosaminoglycan mimetic improves pressure ulcer healing in a rat model of cutaneous ischemia-reperfusion injury","volume":"19","author":"Tong","year":"2011","journal-title":"Wound Repair Regen"},{"issue":"1","key":"2023070812255111500_ojad031-B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jbm.a.30874","article-title":"RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin","volume":"80","author":"Garcia-Filipe","year":"2007","journal-title":"J Biomed Mater Res A"},{"issue":"3","key":"2023070812255111500_ojad031-B13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jbm.a.32124","article-title":"Matrix therapy in regenerative medicine, a new approach to chronic wound healing","volume":"90","author":"Barbier-Chassefi\u00e8re","year":"2009","journal-title":"J Biomed Mater Res A"},{"issue":"2","key":"2023070812255111500_ojad031-B14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/PRS.0b013e318200a910","article-title":"Matrix therapy with RGTA OTR4120 improves healing time and quality in hairless rats with deep second-degree burns","volume":"127","author":"Zakine","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"2023070812255111500_ojad031-B15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.anplas.2010.07.011","article-title":"First applications of matrix therapy in plastic and aesthetic surgery","volume":"55","author":"Zakine","year":"2010","journal-title":"Ann Chir Plast Esthet"},{"issue":"1","key":"2023070812255111500_ojad031-B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/PRS.0b013e318217429b","article-title":"Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial","volume":"128","author":"So","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"2023070812255111500_ojad031-B17","doi-asserted-by":"publisher","first-page":"100180","DOI":"10.1016\/j.wndm.2020.100180","article-title":"Overview of 10 years of practice with CACIPLIQ20\u00ae matrix therapy as a healing agent for hard to heal wounds: efficacy, cost-effectiveness and future perspectives","volume":"28","author":"Barritault","year":"2020","journal-title":"Wound Med"},{"key":"2023070812255111500_ojad031-B18","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3389\/fphar.2019.01649","article-title":"Small leucine-rich proteoglycans in skin wound healing","volume":"10","author":"Pang","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023070812255111500_ojad031-B19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-030-44766-3_16","volume-title":"Textbook on Scar Management","author":"Poetschke","year":"2020"},{"issue":"4","key":"2023070812255111500_ojad031-B20","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s00266-017-0820-4","article-title":"A 1-year follow-up of post-operative scars after the use of a 1210-nm laser-assisted skin healing (LASH) technology: a randomized controlled trial","volume":"41","author":"Casanova","year":"2017","journal-title":"Aesthetic Plast Surg"},{"issue":"5","key":"2023070812255111500_ojad031-B21","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1007\/s00266-021-02196-5","article-title":"The efficacy and safety of botulinum toxin injections in preventing postoperative scars and improving scar quality: a systematic review and meta-analysis","volume":"45","author":"Qiao","year":"2021","journal-title":"Aesthetic Plast Surg"},{"issue":"3","key":"2023070812255111500_ojad031-B22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/PRS.0000000000004110","article-title":"Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial","volume":"141","author":"Hu","year":"2018","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"2023070812255111500_ojad031-B23","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.1038\/s41598-021-93203-x","article-title":"The effect of botulinum toxin injection dose on the appearance of surgical scar","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"2023070812255111500_ojad031-B24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s13555-020-00407-6","article-title":"The Japanese experience with basic fibroblast growth factor in cutaneous wound management and scar prevention: a systematic review of clinical and biological aspects","volume":"10","author":"Abdelhakim","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"2023070812255111500_ojad031-B25","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.burns.2017.03.005","article-title":"Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: results of a randomized phase III clinical trials program","volume":"43","author":"Barret","year":"2017","journal-title":"Burns"},{"key":"2023070812255111500_ojad031-B26"}],"container-title":["Aesthetic Surgery Journal Open Forum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asjopenforum\/advance-article-pdf\/doi\/10.1093\/asjof\/ojad031\/49605397\/ojad031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asjopenforum\/article-pdf\/doi\/10.1093\/asjof\/ojad031\/50841980\/ojad031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asjopenforum\/article-pdf\/doi\/10.1093\/asjof\/ojad031\/50841980\/ojad031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T12:26:13Z","timestamp":1688819173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asjopenforum\/article\/doi\/10.1093\/asjof\/ojad031\/7084902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/asjof\/ojad031","relation":{},"ISSN":["2631-4797"],"issn-type":[{"value":"2631-4797","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023]]},"published":{"date-parts":[[2023]]},"article-number":"ojad031"}}